CollPlant Biotechnologies (CLGN) director reports options and RSUs on Form 3

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd director Penn Elan has filed an initial Form 3 disclosing equity interests in the company. The filing reports options to purchase 10,000 ordinary shares at $4.02 expiring in 2028, 8,000 options at $6.39 expiring in 2030, and 24,000 options at $6.39 expiring in 2032, all held directly.

Elan also holds 7,500 restricted share units, of which 625 are already vested. The remaining 6,875 units vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on continued service. Most of the option grants are already fully vested or largely vested under the disclosed schedule.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Penn Elan

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units	7,500(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(2)	01/14/2019	01/14/2028	Ordinary Shares	10,000(2)	$4.02	D
Options to Purchase Ordinary Shares(2)	08/27/2021	08/27/2030	Ordinary Shares	8,000(2)	$6.39	D
Options to Purchase Ordinary Shares(3)	05/02/2023	05/02/2032	Ordinary Shares	24,000(3)	$6.39	D

Explanation of Responses:

1. Of the restricted share units reported herein, 625 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

2. Fully vested and exercisable.

3. 22,500 options are fully vested and exercisable and the remaining 1,500 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Elan Penn	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the CollPlant Biotechnologies (CLGN) Form 3 for Penn Elan disclose?

The Form 3 shows Penn Elan’s initial equity holdings as a director of CollPlant Biotechnologies. It lists several option grants over ordinary shares and a block of restricted share units, including their exercise prices, expiration dates, and vesting schedules, but no recent share purchases or sales.

How many CollPlant Biotechnologies (CLGN) stock options does Penn Elan hold?

Penn Elan holds options over 10,000 ordinary shares at $4.02, 8,000 shares at $6.39, and 24,000 shares at $6.39. Each grant has its own expiration date between 2028 and 2032, and the filing indicates these options are held directly.

What are the vesting terms of Penn Elan’s CLGN restricted share units?

Penn Elan holds 7,500 restricted share units. Of these, 625 units are already vested. The remaining 6,875 RSUs vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, assuming Elan continues to serve CollPlant Biotechnologies through each vesting date.

When do Penn Elan’s CollPlant Biotechnologies (CLGN) stock options expire?

Elan’s options over ordinary shares expire on three different dates: January 14, 2028 for the 10,000-share grant, August 27, 2030 for the 8,000-share grant, and May 2, 2032 for the 24,000-share grant, as reported in the Form 3.

Does Penn Elan’s Form 3 for CLGN show any recent share purchases or sales?

No, this Form 3 functions as an initial statement of beneficial ownership. It lists existing option awards and restricted share units but does not report open-market purchases, sales, or option exercises. All transaction entries are characterized as holdings rather than new trades.

How much of Penn Elan’s largest CLGN option grant is currently vested?

For the 24,000-share option grant at $6.39, the footnotes state that 22,500 options are fully vested and exercisable. The remaining 1,500 options are scheduled to vest on May 2, 2026, subject to Penn Elan’s continued service with CollPlant Biotechnologies on that date.